|
1
|
Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema.
|
J Allergy Clin Immunol
|
2000
|
1.53
|
|
2
|
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
|
J Clin Oncol
|
2001
|
1.35
|
|
3
|
Stem cell transplantation in a patient with late-onset nemaline myopathy and gammopathy.
|
Neurology
|
2008
|
1.20
|
|
4
|
[Bing-Neel syndrome revealing Waldenström's macroglobulinemia].
|
Rev Neurol (Paris)
|
2009
|
0.98
|
|
5
|
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
|
Leukemia
|
2005
|
0.97
|
|
6
|
Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases.
|
Leukemia
|
2006
|
0.97
|
|
7
|
Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.
|
Am J Transplant
|
2013
|
0.87
|
|
8
|
Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
|
Pharmacogenomics J
|
2012
|
0.82
|
|
9
|
Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.79
|
|
10
|
Expansion of CD4+CD7- T cells, a memory subset with preferential interleukin-4 production, after bone marrow transplantation.
|
Transplantation
|
1997
|
0.78
|
|
11
|
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.
|
Am J Transplant
|
2015
|
0.76
|
|
12
|
Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial.
|
Leukemia
|
2013
|
0.75
|